Farther Finance Advisors LLC Sells 265 Shares of Insulet Corporation $PODD

Farther Finance Advisors LLC lowered its holdings in Insulet Corporation (NASDAQ:PODD) by 29.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 631 shares of the medical instruments supplier’s stock after selling 265 shares during the period. Farther Finance Advisors LLC’s holdings in Insulet were worth $198,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of PODD. Wealth Enhancement Advisory Services LLC raised its position in shares of Insulet by 16.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 2,658 shares of the medical instruments supplier’s stock valued at $694,000 after purchasing an additional 384 shares during the period. Parallel Advisors LLC increased its holdings in Insulet by 10.8% during the 1st quarter. Parallel Advisors LLC now owns 986 shares of the medical instruments supplier’s stock worth $259,000 after acquiring an additional 96 shares during the period. Rhumbline Advisers increased its holdings in Insulet by 7.1% during the 1st quarter. Rhumbline Advisers now owns 152,882 shares of the medical instruments supplier’s stock worth $40,148,000 after acquiring an additional 10,135 shares during the period. Czech National Bank increased its holdings in Insulet by 5.9% during the 1st quarter. Czech National Bank now owns 16,111 shares of the medical instruments supplier’s stock worth $4,231,000 after acquiring an additional 902 shares during the period. Finally, Merit Financial Group LLC bought a new stake in Insulet during the 1st quarter worth approximately $209,000.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on PODD shares. Wells Fargo & Company upped their target price on shares of Insulet from $330.00 to $350.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Morgan Stanley reaffirmed an “overweight” rating on shares of Insulet in a report on Thursday, August 7th. Barclays upped their target price on shares of Insulet from $266.00 to $300.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. Truist Financial initiated coverage on shares of Insulet in a report on Monday, June 16th. They issued a “buy” rating and a $365.00 price target on the stock. Finally, Royal Bank Of Canada increased their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Sixteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $345.47.

Insulet Price Performance

Shares of Insulet stock opened at $305.98 on Thursday. Insulet Corporation has a 52-week low of $225.37 and a 52-week high of $353.50. The stock has a market capitalization of $21.54 billion, a price-to-earnings ratio of 93.00, a price-to-earnings-growth ratio of 2.56 and a beta of 1.40. The company has a fifty day moving average of $320.45 and a 200-day moving average of $297.85. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. During the same quarter in the prior year, the company earned $0.55 EPS. The firm’s revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.